Quick Takeaways
- SLDB - Solid Biosciences Inc. has 26 insiders with reported activity on this page.
- Net insider value flow over the last year: -$2,681,597.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 26 Insiders of Solid Biosciences Inc.
- Symbol
- SLDB on Nasdaq
- Location
- Charlestown, MA
What Changed
- Buy value: ; sell value: $2,681,597.
- Net share flow: -427,620.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$2,681,597.
Buys
$0
Shares: 0
Insiders: 0
Sells
$2,681,597
Shares: 427,620
Insiders: 7
Net
-$2,681,597
Shares: -427,620
Insiders: -7
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 397,470 | $0 | $2,527,978 | -$2,527,978 |
| 3-6 | 0 | 30,150 | $0 | $153,619 | -$153,619 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Solid Biosciences Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 10%+ Owner | $46,252,926 | Filing P/S | 19 Feb 2025 | ||
| Adage Capital Management, L.P. | 10%+ Owner | $32,115,515 | Filing P/S | 18 Feb 2025 | ||
| Adam Koppel | Director, 10%+ Owner | $22,311,238 | Mixed | 11 Jan 2024 | ||
| RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | $14,996,280 | Filing P/S | 19 Feb 2025 | ||
| BCLS II Equity Opportunities GP, LLC | Director, 10%+ Owner | $5,000,005 | Mixed | 11 Jan 2024 | ||
| Alexander Cumbo | President and CEO, Director | $1,727,605 | -$983,857 | -36% | Mixed | 13 Feb 2026 |
| Joel Solomon Zev Schneider | Chief Operating Officer | $1,306,573 | Mixed | 14 Mar 2022 | ||
| Ilan Ganot | Director | $884,781 | -$82,374 | -8.5% | Mixed | 13 Feb 2026 |
| Ian F. Smith | Director | $832,936 | Mixed | 02 Apr 2026 | ||
| David Tyronne Howton | Chief Operating Officer | $786,383 | -$433,538 | -36% | Mixed | 13 Feb 2026 |
| Kevin Tan | CFO & Treasurer | $705,189 | -$329,507 | -32% | Mixed | 13 Feb 2026 |
| Gabriel Brooks | Chief Medical Officer | $650,926 | -$280,915 | -30% | Mixed | 13 Feb 2026 |
| Jessie Hanrahan | Chief Regulatory Officer | $529,301 | -$297,329 | -36% | Mixed | 13 Feb 2026 |
| Paul Herzich | Chief Technology Officer | $508,381 | -$274,077 | -35% | Mixed | 13 Feb 2026 |
| Jennifer Marlowe | Cso | $398,249 | Mixed | 13 Feb 2024 | ||
| Carl Ashley Morris | Chief Scientific Officer | $128,883 | Mixed | 27 Jan 2023 | ||
| Clare Kahn | Director | $15,794 | Filing P/S | 12 Jun 2025 | ||
| Adam Leo Stone | Director | Mixed | 12 Jun 2025 | |||
| Georgia Keresty | Director | Mixed | 12 Jun 2025 | |||
| Sukumar Nagendran | Director | Mixed | 12 Jun 2025 | |||
| Rajeev M. Shah | Director, 10%+ Owner | Mixed | 16 Jun 2021 | |||
| PERCEPTIVE ADVISORS LLC | Director, 10%+ Owner | Mixed | 09 Mar 2026 | |||
| Robert Luther Huffines | Director | Mixed | 13 Dec 2022 | |||
| Erin P. Brennan | Chief Legal Officer, Secretary | Mixed | 02 May 2022 | |||
| Martin I. Freed | Director | Mixed | 12 Jun 2025 | |||
| Lynne Marie Sullivan | Director | Mixed | 12 Jun 2025 |
Top shareholders of Solid Biosciences Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13D/G
3/4/5
13F
|
Director, 10%+ Owner · Company |
13%
|
11,969,079
|
$82,945,717 | +$238,392 | 09 Mar 2026 | |
| Bain Capital Life Sciences Investors, LLC |
3/4/5
13F
|
10%+ Owner · Company |
8.5%
from 13F
|
11,478,752
mixed-class rows
|
$46,252,926 | — | 19 Feb 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
8.3%
|
7,690,405
|
$43,373,884 | — | 31 Dec 2025 | |
| Vestal Point Capital, LP |
13D/G
13F
|
Company |
7.5%
|
5,815,000
|
$32,796,600 | +$22,906,533 | 31 Dec 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
3/4/5
|
Company · 10%+ Owner |
9.9%
from 13D/G
|
5,811,423
|
$32,776,426 | — | 31 Dec 2025 | |
| Adage Capital Management, L.P. |
3/4/5
13D/G
|
10%+ Owner |
1.8%
from 13D/G
|
4,248,084
|
$32,115,515 | — | 18 Feb 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.1%
from 13D/G
|
4,869,682
|
$27,465,007 | — | 31 Dec 2025 | |
| Invus Global Management, LLC |
13D/G
|
Raymond Debbane |
9.6%
|
7,415,905
|
$27,216,371 | +$13,457,391 | 31 Mar 2025 | |
| Adam Koppel |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
4,044,232
mixed-class rows
|
$22,311,238 | — | 11 Jan 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.7%
|
3,454,959
|
$19,485,969 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.9%
|
2,663,863
|
$15,024,188 | — | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
2.8%
|
2,612,000
|
$14,731,680 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.6%
|
2,416,108
|
$13,626,849 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
2.2%
|
2,029,898
|
$11,448,625 | — | 31 Dec 2025 | |
| Redmile Group, LLC |
13F
|
Company |
2%
|
1,860,542
|
$10,493,457 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
1.8%
|
1,682,805
|
$9,491,020 | — | 31 Dec 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.7%
|
1,603,336
|
$9,042,815 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.7%
|
1,599,233
|
$9,019,674 | — | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.5%
|
1,400,000
|
$7,896,000 | — | 31 Dec 2025 | |
| Monashee Investment Management LLC |
13F
|
Company |
1.5%
|
1,349,771
|
$7,612,708 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
1,267,392
|
$7,149,537 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.2%
|
1,087,413
|
$6,133,009 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.1%
|
1,006,306
|
$5,675,566 | — | 31 Dec 2025 | |
| Finepoint Capital LP |
13F
|
Company |
1%
|
961,251
|
$5,421,456 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.98%
|
911,409
|
$5,140,346 | — | 31 Dec 2025 | |
| BCLS II Equity Opportunities GP, LLC |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
904,160
|
$5,000,005 | — | 11 Jan 2024 | |
| Birchview Capital, LP |
13F
|
Company |
0.76%
|
705,955
|
$3,981,586 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.73%
|
679,084
|
$3,830,140 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.54%
|
499,293
|
$2,816,013 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.45%
|
418,371
|
$2,359,612 | — | 31 Dec 2025 | |
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.45%
|
413,625
|
$2,332,845 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.44%
|
412,777
|
$2,328,063 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.43%
|
394,976
|
$2,227,665 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.42%
|
394,266
|
$2,223,660 | — | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.39%
|
360,937
|
$2,035,685 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.37%
|
344,294
|
$1,941,818 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.34%
|
316,823
|
$1,786,882 | — | 31 Dec 2025 | |
| Alexander Cumbo |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
805,318
mixed-class rows
|
$1,727,605 | -$983,857 | 13 Feb 2026 | |
| Boxer Capital Management, LLC |
13F
|
Company |
0.32%
|
300,000
|
$1,692,000 | — | 31 Dec 2025 | |
| Joel Solomon Zev Schneider |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
236,270
|
$1,306,573 | — | 14 Mar 2022 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.24%
|
226,755
|
$1,278,898 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.23%
|
213,409
|
$1,203,627 | — | 31 Dec 2025 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.21%
|
199,436
|
$1,124,819 | — | 31 Dec 2025 | |
| APIS CAPITAL ADVISORS, LLC |
13F
|
Company |
0.21%
|
196,000
|
$1,105,440 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.2%
|
185,682
|
$1,047,246 | — | 31 Dec 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.2%
|
182,869
|
$1,031,380 | — | 31 Dec 2025 | |
| David M. Knott Jr. |
13F
|
Individual |
0.18%
|
162,440
|
$916,162 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.17%
|
161,537
|
$911,069 | — | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.17%
|
160,409
|
$904,707 | — | 31 Dec 2025 | |
| Ilan Ganot |
3/4/5
|
Director |
—
mixed-class rows
|
304,287
mixed-class rows
|
$884,781 | -$82,374 | 13 Feb 2026 |
Recent Insider Transactions by Companies or Individuals for Solid Biosciences Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Ian F. Smith | SLDB | Common Stock | Options Exercise | 2.62% | 3,441 | 134,705 | 02 Apr 2026 | Direct | ||
| Ian F. Smith | SLDB | Restricted Stock Units | Options Exercise | -25% | -3,441 | 10,320 | 02 Apr 2026 | Direct | ||
| Perceptive Advisors Llc | SLDB | Pre-Funded Warrant (right to buy) | Award | 8,912,655 | 8,912,655 | 09 Mar 2026 | See footnote | |||
| Alexander Cumbo | SLDB | Common Stock | Sale | -6.6% | $96,923 | $5.82 | -16,644 | 235,405 | 18 Feb 2026 | Direct |
| Jessie Hanrahan | SLDB | Common Stock | Sale | -5.27% | $24,074 | $5.82 | -4,134 | 74,318 | 18 Feb 2026 | Direct |
| Ilan Ganot | SLDB | Common Stock | Sale | -8.82% | $15,478 | $5.82 | -2,658 | 27,474 | 18 Feb 2026 | Wife |
| Paul Herzich | SLDB | Common Stock | Sale | -4.74% | $21,057 | $5.82 | -3,616 | 72,638 | 18 Feb 2026 | Direct |
| David Tyronne Howton | SLDB | Common Stock | Sale | -6.64% | $43,494 | $5.82 | -7,469 | 105,077 | 18 Feb 2026 | Direct |
| Gabriel Brooks | SLDB | Common Stock | Sale | $0 | 0 | 89,466 | 18 Feb 2026 | Direct | ||
| Kevin Tan | SLDB | Common Stock | Sale | -5.16% | $31,469 | $5.82 | -5,404 | 99,422 | 18 Feb 2026 | Direct |
| Alexander Cumbo | SLDB | Common Stock | Options Exercise | 13.5% | 30,031 | 252,049 | 13 Feb 2026 | Direct | ||
| Alexander Cumbo | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -30,031 | 60,063 | 13 Feb 2026 | Direct | ||
| Jessie Hanrahan | SLDB | Common Stock | Options Exercise | 11.6% | 8,125 | 78,452 | 13 Feb 2026 | Direct | ||
| Jessie Hanrahan | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -8,125 | 16,250 | 13 Feb 2026 | Direct | ||
| Ilan Ganot | SLDB | Common Stock | Options Exercise | 19.2% | 4,861 | 30,132 | 13 Feb 2026 | Wife | ||
| Ilan Ganot | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -4,861 | 9,722 | 13 Feb 2026 | Wife | ||
| Paul Herzich | SLDB | Common Stock | Options Exercise | 10.4% | 7,187 | 76,254 | 13 Feb 2026 | Direct | ||
| Paul Herzich | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -7,187 | 14,376 | 13 Feb 2026 | Direct | ||
| David Tyronne Howton | SLDB | Common Stock | Options Exercise | 15% | 14,687 | 112,546 | 13 Feb 2026 | Direct | ||
| David Tyronne Howton | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -14,687 | 29,376 | 13 Feb 2026 | Direct | ||
| Gabriel Brooks | SLDB | Common Stock | Options Exercise | 13% | 10,937 | 95,029 | 13 Feb 2026 | Direct | ||
| Gabriel Brooks | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -10,937 | 21,876 | 13 Feb 2026 | Direct | ||
| Kevin Tan | SLDB | Common Stock | Options Exercise | 11.3% | 10,625 | 104,826 | 13 Feb 2026 | Direct | ||
| Kevin Tan | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -10,625 | 21,250 | 13 Feb 2026 | Direct | ||
| David Tyronne Howton | SLDB | Common Stock | Sale | -16.2% | $121,713 | $6.44 | -18,894 | 97,859 | 04 Feb 2026 | Direct |
| Alexander Cumbo | SLDB | Common Stock | Sale | -18% | $315,093 | $6.44 | -48,913 | 222,018 | 04 Feb 2026 | Direct |
| Ilan Ganot | SLDB | Common Stock | Sale | -22.2% | $46,414 | $6.44 | -7,205 | 25,271 | 04 Feb 2026 | Wife |
| Kevin Tan | SLDB | Common Stock | Sale | -13.6% | $95,231 | $6.44 | -14,783 | 94,201 | 04 Feb 2026 | Direct |
| Gabriel Brooks | SLDB | Common Stock | Sale | -13% | $81,271 | $6.44 | -12,616 | 84,092 | 04 Feb 2026 | Direct |
| Jessie Hanrahan | SLDB | Common Stock | Sale | -14.9% | $79,545 | $6.44 | -12,348 | 70,327 | 04 Feb 2026 | Direct |
| Paul Herzich | SLDB | Common Stock | Sale | -13.6% | $70,249 | $6.44 | -10,905 | 69,067 | 04 Feb 2026 | Direct |
| Kevin Tan | SLDB | Common Stock | Sale | -19.8% | $172,747 | $6.44 | -26,837 | 108,984 | 02 Feb 2026 | Direct |
| Jessie Hanrahan | SLDB | Common Stock | Sale | -24.3% | $170,803 | $6.44 | -26,535 | 82,675 | 02 Feb 2026 | Direct |
| Gabriel Brooks | SLDB | Common Stock | Sale | -22.7% | $182,390 | $6.44 | -28,335 | 96,708 | 02 Feb 2026 | Direct |
| Paul Herzich | SLDB | Common Stock | Sale | -24.7% | $168,969 | $6.44 | -26,250 | 79,972 | 02 Feb 2026 | Direct |
| Alexander Cumbo | SLDB | Common Stock | Sale | -22.8% | $516,613 | $6.44 | -80,258 | 270,931 | 02 Feb 2026 | Direct |
| David Tyronne Howton | SLDB | Common Stock | Sale | -24.4% | $243,128 | $6.44 | -37,771 | 116,753 | 02 Feb 2026 | Direct |
| Kevin Tan | SLDB | Common Stock | Options Exercise | 32.2% | 33,075 | 135,821 | 31 Jan 2026 | Direct | ||
| Kevin Tan | SLDB | Restricted Stock Units | Options Exercise | -25% | -33,075 | 99,225 | 31 Jan 2026 | Direct | ||
| Jessie Hanrahan | SLDB | Common Stock | Options Exercise | 33.9% | 27,625 | 109,210 | 31 Jan 2026 | Direct | ||
| Jessie Hanrahan | SLDB | Restricted Stock Units | Options Exercise | -25% | -27,625 | 82,875 | 31 Jan 2026 | Direct | ||
| Gabriel Brooks | SLDB | Common Stock | Options Exercise | 29.2% | 28,225 | 125,043 | 31 Jan 2026 | Direct | ||
| Gabriel Brooks | SLDB | Restricted Stock Units | Options Exercise | -25% | -28,225 | 84,675 | 31 Jan 2026 | Direct | ||
| Paul Herzich | SLDB | Common Stock | Options Exercise | 30.3% | 24,675 | 106,222 | 31 Jan 2026 | Direct | ||
| Paul Herzich | SLDB | Restricted Stock Units | Options Exercise | -25% | -24,675 | 74,025 | 31 Jan 2026 | Direct | ||
| Ilan Ganot | SLDB | Common Stock | Options Exercise | 85.8% | 15,000 | 32,476 | 31 Jan 2026 | Wife | ||
| Ilan Ganot | SLDB | Restricted Stock Units | Options Exercise | -25% | -15,000 | 45,000 | 31 Jan 2026 | Wife | ||
| Alexander Cumbo | SLDB | Common Stock | Options Exercise | 40% | 100,400 | 351,189 | 31 Jan 2026 | Direct | ||
| Alexander Cumbo | SLDB | Restricted Stock Units | Options Exercise | -25% | -100,400 | 301,200 | 31 Jan 2026 | Direct | ||
| David Tyronne Howton | SLDB | Common Stock | Options Exercise | 37.8% | 42,275 | 154,254 | 31 Jan 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.